Cart (0)
Your shopping cart is empty!
Longidaza suppositories 3000 IU N10
Longidaza suppositories 3000 IU N10
Product Code: 933

Longidaza suppositories 3000 IU N10

Compare this Product
Longidaza suppositories 3000ME, No. 10

Adults and adolescents over 12 years of age in the form of monotherapy and as part of complex therapy for diseases accompanied by hyperplasia of the connective tissue (including against the background of an inflammatory process).

In urology:

  • chronic prostatitis;

  • interstitial cystitis;

  • strictures of the urethra and ureters;

  • Peyronie's disease;

  • the initial stage of benign prostatic hyperplasia;

  • prevention of the formation of scars and strictures after surgical interventions on the urethra, bladder, ureters.

In gynecology:

  • prevention and treatment of adhesions in the small pelvis in chronic inflammatory diseases of the internal genital organs;

  • prevention and treatment of adhesions in the small pelvis after gynecological manipulations (including artificial abortions, previous surgical interventions on the pelvic organs);

  • intrauterine synechiae;

  • tubal peritoneal infertility;

  • chronic endomyometritis.

In dermatovenerology:

  • limited scleroderma;

  • prevention of fibrotic complications of sexually transmitted infections.

In surgery:

  • prevention and treatment of adhesions after surgical interventions on the abdominal organs;

  • long-term non-healing wounds.

In pulmonology and phthisiology:

  • pneumofibrosis;

  • siderosis;

  • tuberculosis (cavernous fibrous, infiltrative, tuberculoma);

  • interstitial pneumonia;

  • fibrosing alveolitis;

  • pleurisy.

To increase the bioavailability of antibiotic therapy in urology, gynecology, dermatovenerology, surgery and pulmonology.

LongidazaЃ suppositories 3000 IU are recommended for rectal or intravaginal use 1 time / day at night, for a course - 10-20 injections.

For adults intravaginally: 1 suppository 1 time / day at night; the suppository is inserted into the vagina while lying down.

For adolescents aged 12 to 18 years, suppositories are administered only rectally.

Adults and adolescents over 12 years old rectally: 1 suppository 1 time / day after bowel cleansing.

The treatment regimen is adjusted depending on the severity, stage and duration of the disease. Perhaps the appointment of the drug every other day or at intervals of 2-3 days.

Recommended treatment regimens

In urology

1 suppository every other day - 10 injections, then after 2-3 days - 10 injections. General course of 20 introductions.

In gynecology

Rectally or intravaginally, 1 suppository every 2 days - 10 injections, then, if necessary, supportive therapy is prescribed.

In dermatovenerology

1 suppository in 1-2 days - 10-15 injections.

In surgery

1 suppository every 2-3 days - 10 injections.

In pulmonology and phthisiology

1 suppository in 2-4 days - 10-20 insertions.

If necessary, a repeated course of LongidazaЃ is recommended no earlier than 3 months later or long-term maintenance therapy - 1 suppository 1 time / 5-7 days for 3-4 months.

Suppositories vaginal and rectal torpedo-shaped, light yellow in color, with a weak specific smell of cocoa butter, marbling of staining is allowed.

1 supp. bovhyaluronidase azoxymer (longidaseЃ) 3000 IU

Excipients: cocoa butter - until a suppository weighing 1.3 g is obtained.

  • pulmonary hemorrhage and hemoptysis;

  • fresh vitreous hemorrhage;

  • malignant neoplasms;

  • acute renal failure;

  • pregnancy;

  • lactation period;

  • children under 12 years of age (there are no clinical trial results);

  • hypersensitivity to drugs based on hyaluronidase.

Use with caution and no more than 1 time per week in patients with chronic renal failure, a history of pulmonary hemorrhage.

pharmachologic effect

LongidaseЃ possesses hyaluronidase (enzymatic) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory effect.

Prolonged action is achieved by covalent binding of the enzyme to a physiologically active polymeric carrier (azoxymer). LongidaseЃ exhibits anti-fibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and TNF?), Increases the humoral immune response and the body's resistance to infection.

The pronounced anti-fibrotic properties of the LongidazaЃ drug are provided by the conjugation of hyaluronidase with the carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors: the enzymatic activity of the LongidazaЃ drug remains when heated to 37 ? C for 20 days, while native hyaluronidase in the same conditions loses its activity during the day.

In the LongidazaЃ preparation, the simultaneous local presence of the hyaluronidase enzyme and a carrier capable of binding the enzyme inhibitors released during hydrolysis of the matrix components and stimulators of collagen synthesis (ions of iron, copper, heparin and others) is ensured. Due to these properties, LongidaseЃ has not only the ability to depolymerize the connective tissue matrix in fibrous-granulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.

A specific substrate for testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (rupture of the bond between C1 of acetylglycosamine and C4 of glucuronic or induric acids) glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water and metal ions decreases, the permeability of tissue barriers temporarily increases, fluid movement in the intercellular space is facilitated, the elasticity of connective tissue increases , which manifests itself in a decrease in tissue swelling, flattening of scars, an increase in the range of motion of joints, a decrease in contractures and the prevention of their formation, a decrease in the adhesion process.

Biochemical, immunological, histological and electron microscopic studies have shown that LongidaseЃ does not damage normal connective tissue, but causes destruction of the connective tissue that has changed in composition and structure in the area of ??fibrosis.

LongidaseЃ has no mutagenic, embryotoxic, teratogenic and carcinogenic effects.

The drug is well tolerated by patients, there are no local and general allergic reactions.

The use of the drug LongidazaЃ in therapeutic doses during or after surgical treatment does not cause a deterioration in the course of the postoperative period or the progression of the infectious process; does not slow down the restoration of bone tissue.


Absorption and distribution

An experimental study of pharmacokinetics made it possible to establish that when administered rectally, LongidazaЃ is characterized by a high rate of distribution in the body, is well absorbed into the systemic circulation and reaches Cmax in the blood after 1 hour. The bioavailability of LongidazaЃ when administered rectally is high - about 90%.

The half-life is about 0.5 hours. The drug penetrates into all organs and tissues (including through the BBB and the blood-ophthalmic barrier). Does not accumulate in tissues.


“1 / 2 from 42 hours to 84 hours. It is excreted mainly by the kidneys.

Side effect

Very rare: local reactions in the form of redness, edema, itching of the perianal zone, vaginal itching due to individual sensitivity to the components of the drug.

In the event of adverse reactions, as well as in the event of an adverse reaction not specified in the instructions, you should consult your doctor.

Application during pregnancy and lactation

The use of the drug during pregnancy and during breastfeeding is contraindicated (there is no clinical experience of use).

Application for impaired renal function

The use of the drug is contraindicated in acute renal failure.

Use with caution and no more than 1 time per week in patients with renal insufficiency.

Application in children

The use of the drug in children under 12 years of age is contraindicated (there are no results of clinical studies)

special instructions

If an allergic reaction develops, the use of LongidazaЃ should be discontinued.

When used against the background of an exacerbation of infection, to prevent the spread of infection, it is necessary to prescribe LongidazaЃ under the cover of antimicrobial agents.

The drug should not be used if there are visual signs of its unsuitability (packaging defect, discoloration of the suppository).

If the next dose is missed, then the drug should be used as usual (do not enter a double dose).

If it is necessary to stop taking the LongidazaЃ drug, cancellation can be carried out immediately, without a gradual dose reduction.

Influence on the ability to drive vehicles and use mechanisms

The use of LongidazaЃ does not affect the ability to drive vehicles, maintain mechanisms and other types of work that require an increased concentration of attention and speed of psychomotor reactions.


Overdose symptoms can be manifested by chills, fever, dizziness, hypotension.

Treatment: the administration of the drug is stopped and symptomatic therapy is prescribed.

Drug interactions

LongidazaЃ drug can be combined with antibiotics, antiviral, antifungal drugs, bronchodilators.

When administered in combination with other drugs (antibiotics, local anesthetics, diuretics), the possibility of increasing bioavailability and enhancing their action should be taken into account.

When used together with large doses of salicylates, cortisone, ACTH, estrogens or antihistamines, the enzymatic activity of LongidazaЃ may be reduced.

Do not use LongidazaЃ at the same time as drugs containing furosemide, benzodiazepines, phenytoin.